I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome Associated with Severe and Critically-Ill Patients with Coronavirus Disease (COVID-19) -The clinical study will explore the potential of TJM2, a proprietary mAb against GM-CSF, to fight "cytokine storm” during severe COVID-19 disease -The study to be conducted initially in the United...

I-Mab to Report Financial Results for Full Year 2019 and Provide Corporate Update on March 31, 2020 SHANGHAI, China and ROCKVILLE, MD., March 11, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and...

I-Mab Announces Upcoming Participation at March Conferences SHANGHAI, China and ROCKVILLE, MD., Feb. 25, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and...

I-Mab Announces Partial Exercise of Over-Allotment Option in Initial Public Offering SHANGHAI, China and ROCKVILLE, MD., Feb. 10, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and...

I-MAB Announces Pricing of U.S. Initial Public Offering SHANGHAI, China and ROCKVILLE, Md., Jan. 17, 2020 (GLOBE NEWSWIRE) -- I-Mab (“I-Mab” or the “Company”) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery,...